Shore Capital reaffirmed their hold rating on shares of GlaxoSmithKline (LON:GSK) in a report issued on Thursday, Digital Look reports.
Several other analysts have also recently commented on the company. Jefferies Financial Group reiterated a buy rating on shares of GlaxoSmithKline in a research report on Friday, May 24th. Credit Suisse Group set a GBX 1,700 ($22.21) target price on GlaxoSmithKline and gave the company a neutral rating in a report on Thursday, July 25th. Bryan, Garnier & Co dropped their target price on GlaxoSmithKline from GBX 1,710 ($22.34) to GBX 1,660 ($21.69) and set a neutral rating for the company in a report on Thursday, May 2nd. Morgan Stanley initiated coverage on GlaxoSmithKline in a report on Monday, June 17th. They issued an underweight rating and a GBX 1,520 ($19.86) target price for the company. Finally, Kepler Capital Markets upped their target price on GlaxoSmithKline from GBX 1,440 ($18.82) to GBX 1,540 ($20.12) and gave the company a hold rating in a report on Tuesday, June 11th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average price target of GBX 1,628.56 ($21.28).
Shares of GSK opened at GBX 1,691.20 ($22.10) on Thursday. The company has a debt-to-equity ratio of 1,127.74, a quick ratio of 0.44 and a current ratio of 0.71. GlaxoSmithKline has a one year low of GBX 1,408.80 ($18.41) and a one year high of GBX 1,749.40 ($22.86). The stock has a market capitalization of $84.36 billion and a price-to-earnings ratio of 19.05. The stock has a 50 day moving average price of GBX 1,663.51 and a 200 day moving average price of GBX 1,580.91.
In related news, insider Vivienne Cox bought 434 shares of the company’s stock in a transaction on Wednesday, July 24th. The stock was bought at an average cost of GBX 1,654 ($21.61) per share, for a total transaction of £7,178.36 ($9,379.80). Over the last 90 days, insiders acquired 456 shares of company stock valued at $753,737.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Featured Story: Why is Cost of Capital Important?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.